India’s Sun Sees Specialty Spend Checking Profit Growth
Executive Summary
India’s biggest generics company cautions that investments to ramp up its specialty business are expected to constrain profit growth over the near term, as a one-off charge cuts fourth-quarter income in half.
You may also be interested in...
Concerns Over Alleged Lapses By Sun Fading?
Early indications that a whistleblower’s allegations of certain serious irregularities by Sun Pharma may not hold water lifted its shares, though it remains unclear if the issue stands completely closed.
Sun’s Ilumya Set For Phase III In Psoriatic Arthritis After ‘Promising’ Results
Sun releases what it says are promising interim data from a Phase II study on Ilumya, its flagship first novel biologic, in the additional indication of psoriatic arthritis, where the antibody met the primary endpoint in its first trial in this setting.
Top US Court Lifts Discovery Stay On Price-Fixing
The US Supreme Court has lifted a stay on document discovery in a multi-state lawsuit in which dozens of generics companies – including Teva, Mylan and Pfizer – are accused of price fixing. The ruling will allow a swathe of documents to be released in what Connecticut’s attorney general has said is potentially “the largest cartel case” in US history.